Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase. Issue 3 (28th February 2018)

• Record Type: Journal Article
• Authors: Matsueda, Satoko; Itoh, Kyogo; Shichijo, Shigeki
• Is Part Of: Cancer science. Volume 109:Issue 3(2018)
• Page Start: 611
• Page End: 617
• Publication Date: 2018-02-28
• Subjects: anti‐Lck‐486 peptide antibody -- cancer vaccine -- dendritic cells -- lymphocyte‐specific protein tyrosine kinase -- T‐cell epitope peptide; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13522
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Although humoral responses against CTL epitope peptides from lymphocyte‐specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined. We investigated the biological activity of mAb against CTL epitope peptide of Lck antigen at positions 486‐494 (anti‐Lck‐486 mAb). This mAb induced dendritic cell maturation from murine bone marrow cells by the immune complex form in vitro, and inhibited tumor growth in association with a suppression of tumor‐infiltrating T cells, including T regulatory cells in a murine model using female BALB/cCrlCrlj mice (H‐2K d ). More potent tumor inhibition was observed when this mAb was given prior to peptide vaccination. These results may help to unveil the biological activity of anti‐Lck peptide antibodies against CTL epitope peptides. Abstract : Anti‐Lck486 monoclonal antibody induced dendritic cell maturation from murine bone marrow cells in vitro, and inhibited tumor growth in association with a suppression of tumor infiltrating T cells in a murine model using the BALB/cCrlCrlj mice. More potent tumor inhibition was observed when this monoclonal antibody was administered prior to the peptide vaccination.